TY - JOUR
T1 - Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy
T2 - Results from a prospective multicenter phase 2 trial
AU - Anwar, Sidra
AU - Tan, Wei
AU - Yu, Jinhee
AU - Hutson, Alan
AU - Javle, Milind
AU - Iyer, Renuka
N1 - Publisher Copyright:
© Pioneer Bioscience Publishing Company.
PY - 2014
Y1 - 2014
N2 - Purpose: Pancreatic cancer is rapidly fatal with median survival of only 6 months (mo). Quality-of-life (QoL) was analyzed prospectively in a phase 2 study of gemcitabine (G), capecitabine (C) and bevacizumab (B) in APC patients. Methods: A total of 50 patients with APC received B 15 mg/kg, C 1,300 mg/m2 daily for 2 weeks and G 1,000 mg/m2 weekly 2 times cycles were repeated every 21 days. Endpoints: progression free survival (PFS), overall survival (OS) and assessment of QoL prior to each cycle using the European organization for research and treatment of cancer (EORTC) PAN-26 QoL questionnaire. An exact 95% confidence interval (CI) (Clopper-Pearson method) was used to assess rate of improved QoL (defined as >5 % decrease in two consecutive scores compared with baseline). Results: Patient characteristics- Stage IIB/III/IV: 3/5/42; Sex: 28 M/22 F; Median age: 64 years. QoL in patients- improved: 56%, no improvement: 24%; unevaluable: 20%. Median PFS: 5.8 mo, OS: 9.8 mo. QoL improvement rate: 28/40=0.7 (95% CI: 0.53-0.83) in evaluable patients. Using QoL improvement rate, no significant difference was seen in patients with OS ≥6 mo compared to OS <6 mo. However QoL scores at 3 and 6 weeks from start of treatment correlated strongly with ≥6 mo survival (P value 0.0092 and 0.0081, respectively). Conclusions: Baseline score and change in QoL scores of patients on G, C and B were not predictive of survival ≥6 mo. Post treatment scores at 3 and 6 weeks from start of therapy however, were predictive of survival ≥6 mo suggesting the potential predictive value of this tool for use in future studies.
AB - Purpose: Pancreatic cancer is rapidly fatal with median survival of only 6 months (mo). Quality-of-life (QoL) was analyzed prospectively in a phase 2 study of gemcitabine (G), capecitabine (C) and bevacizumab (B) in APC patients. Methods: A total of 50 patients with APC received B 15 mg/kg, C 1,300 mg/m2 daily for 2 weeks and G 1,000 mg/m2 weekly 2 times cycles were repeated every 21 days. Endpoints: progression free survival (PFS), overall survival (OS) and assessment of QoL prior to each cycle using the European organization for research and treatment of cancer (EORTC) PAN-26 QoL questionnaire. An exact 95% confidence interval (CI) (Clopper-Pearson method) was used to assess rate of improved QoL (defined as >5 % decrease in two consecutive scores compared with baseline). Results: Patient characteristics- Stage IIB/III/IV: 3/5/42; Sex: 28 M/22 F; Median age: 64 years. QoL in patients- improved: 56%, no improvement: 24%; unevaluable: 20%. Median PFS: 5.8 mo, OS: 9.8 mo. QoL improvement rate: 28/40=0.7 (95% CI: 0.53-0.83) in evaluable patients. Using QoL improvement rate, no significant difference was seen in patients with OS ≥6 mo compared to OS <6 mo. However QoL scores at 3 and 6 weeks from start of treatment correlated strongly with ≥6 mo survival (P value 0.0092 and 0.0081, respectively). Conclusions: Baseline score and change in QoL scores of patients on G, C and B were not predictive of survival ≥6 mo. Post treatment scores at 3 and 6 weeks from start of therapy however, were predictive of survival ≥6 mo suggesting the potential predictive value of this tool for use in future studies.
KW - Biomarkers
KW - European organization for research and treatment of cancer (EORTC)
KW - Neoplasm
KW - Outcomes
KW - Palliative care
KW - Pancreas
KW - Pancreatic cancer
KW - Quality of life (QoL)
KW - Supportive oncology
UR - http://www.scopus.com/inward/record.url?scp=84995791143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995791143&partnerID=8YFLogxK
U2 - 10.3978/j.issn.2078-6891.2014.070
DO - 10.3978/j.issn.2078-6891.2014.070
M3 - Article
C2 - 25436122
AN - SCOPUS:84995791143
SN - 2078-6891
VL - 5
SP - 433
EP - 439
JO - Journal of Gastrointestinal Oncology
JF - Journal of Gastrointestinal Oncology
IS - 6
ER -